The pathogenesis of hepatitis C virus is influenced by cytomegalovirus

Clinical Infectious Diseases

Volumn 35, Issue 8, 2002, Pages 974-981

  Razonable, Raymund R ^a   Burak, Kelly W ^a   Van Cruijsen, Hester ^a   Brown, Robert A ^a   Charlton, Michael R ^a   Smith, Thomas F ^a   Espy, Mark J ^a   Kremers, Walter ^a   Wilson, Jennie A ^a   Groettum, Cynthia ^a   Wiesner, Russell ^a   Paya, Carlos V ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALLOGRAFT; ARTICLE; CYTOMEGALOVIRUS; DISEASE ACTIVITY; FEMALE; GRAFT FAILURE; HEPATITIS C VIRUS; HUMAN; HUMAN HERPESVIRUS 6; HUMAN TISSUE; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; VIRUS INFECTION; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION;

ADULT; AGED; CYTOMEGALOVIRUS; FEMALE; HEPACIVIRUS; HUMANS; MALE; MIDDLE AGED; VIRAL INTERFERENCE; VIRUS REPLICATION;

EID: 0037108614     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/342911     Document Type: Article

References (48)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345:41-52.
2. Rosen HR, O’Reilly PM, Shackleton CR, et al. Graft loss following liver transplantation in patients with chronic hepatitis C. Transplantation 1996; 62:1773-6.
3. Rosen HR, Gretch DR, Oehlke M, et al. Timing and severity of initial hepatitis C recurrence as predictors of long-term liver allograft injury. Transplantation 1998; 65:1178-82.
4. Rosen HR, Martin P. Hepatitis C infection in patients undergoing liver retransplantation. Transplantation 1998; 66:1612-6.
5. Chazouilleres O, Kim M, Combs C, et al. Quantitation of hepatitis C virus RNA in liver transplant recipients. Gastroenterology 1994; 106: 994-9.
6. Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28:823-30.
7. Sreekumar R, Gonzalez-Koch A, Maor-Kendler Y, et al. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000; 32:1125-30.
8. Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334:815-20.
9. Gretch DR, Bacchi CE, Corey L, et al. Persistent hepatitis C virus infection after liver transplantation: clinical and virological features. Hepatology 1995; 22:1-9.
10. Rosen HR, Shackleton CR, Higa L, et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997; 92:1453-7.
11. Sheiner PA, Schwartz ME, Mor E, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21:30-4.
12. Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. JAMA 1989; 261:3607-9.
13. Falagas ME, Snydman DR, Griffith J, Ruthazer R, Werner BG. Effect of cytomegalovirus infection status on first-year mortality rates among orthotopic liver transplant recipients: the Boston Center for Liver Transplantation CMVIG Study Group. Ann Intern Med 1997; 126: 275-9.
14. George MJ, Snydman DR, Werner BG, et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group. Am J Med 1997; 103:106-13.
15. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989; 261:3561-6.
16. Patel R, Portela D, Badley AD, et al. Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation. Transplantation 1996; 62:926-34.
17. Evans PC, Soin A, Wreghitt TG, Taylor CJ, Wight DG, Alexander GJ. An association between cytomegalovirus infection and chronic rejection after liver transplantation. Transplantation 2000; 69:30-5.
18. Wagner JA, Ross H, Hunt S, et al. Prophylactic ganciclovir treatment reduces fungal as well as cytomegalovirus infections after heart transplantation. Transplantation 1995; 60:1473-7.
19. Rosen HR, Chou S, Corless CL, et al. Cytomegalovirus viremia: risk factor for allograft cirrhosis after liver transplantation for hepatitis C. Transplantation 1997; 64:721-6.
20. Teixeira R, Pastacaldi S, Davies S, et al. The influence of cytomegalovirus viraemia on the outcome of recurrent hepatitis C after liver transplantation. Transplantation 2000; 70:1454-8.
21. Burak KW, Kremers WK, Batts KP, et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002; 8:362-9.
22. Noraz N, Lathey JL, Spector SA. Human cytomegalovirus-associated immunosuppression is mediated through interferon-α. Blood 1997; 89:2443-52.
23. Rook AH. Interactions of cytomegalovirus with the human immune system. Rev Infect Dis 1988; 10(Suppl 3):S460-7.
24. Sia IG, Wilson JA, Groettum CM, Espy MJ, Smith TF, Paya CV. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid-organ transplantation. J Infect Dis 2000; 181:717-20.
25. Mendez JC, Dockrell DH, Espy MJ, et al. Human β-herpesvirus interactions in solid-organ transplant recipients. J Infect Dis 2001; 183: 179-84.
26. Flamand L, Gosselin J, D’Addario M, et al. Human herpesvirus 6 induces interleukin-1 β and tumor necrosis factor α, but not interleukin-6, in peripheral blood mononuclear cell cultures. J Virol 1991; 5:5105-10.
27. Flamand L, Gosselin J, Stefanescu I, Ablashi D, Menezes J. Immunosuppressive effect of human herpesvirus 6 on T-cell functions: suppression of interleukin-2 synthesis and cell proliferation. Blood 1995; 85:1263-71.
28. Atedzoe BN, Menezes J, D’Addario M, Xu J, Ongradi J, Ahmad A. Modulatory effects of human herpes virus-7 on cytokine synthesis and cell proliferation in human peripheral blood mononuclear cell cultures. J Leukoc Biol 1999; 66:822-8.
29. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696-9.
30. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1:431-5.
31. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-7.
32. Razonable RR, Brown RA, Espy MJ, et al. Comparative quantitation of cytomegalovirus (CMV) DNA in solid organ transplant recipients with CMV infection by using two high-throughput automated systems. J Clin Microbiol 2001; 39:4472-6.
33. Razonable RR, Fanning C, Brown RA, et al. Selective reactivation of human herpesvirus 6 variant a occurs in critically ill immunocompetent hosts. J Infect Dis 2002; 185:110-3.
34. Strasberg SM, Howard TK, Molmenti EP, Hertl M. Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation. Hepatology 1994; 20:829-38.
35. Adam R, Sanchez C, Astarcioglu I, Bismuth H. Deleterious effect of extended cold ischemia time on the posttransplant outcome of aged livers. Transplant Proc 1995; 27:1181-3.
36. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-70.
37. Christensen E, Schlichting P, Fauerholdt L, et al. Prognostic value of Child-Turcotte criteria in medically treated cirrhosis. Hepatology 1984; 4:430-5.
38. Fulton B, Markham A. Mycophenolate mofetil: a review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs 1996; 51:278-98.
39. Rosen HR, Martin P. OKT3 and hepatitis C: defining the risks. Transplantation 1997; 63:171-2.
40. Prosch S, Wendt CE, Reinke P, et al. A novel link between stress and human cytomegalovirus (HCMV) infection: sympathetic hyperactivity stimulates HCMV activation. Virology 2000; 272:357-65.
41. Kutza AS, Muhl E, Hackstein H, Kirchner H, Bein G. High incidence of active cytomegalovirus infection among septic patients. Clin Infect Dis 1998; 26:1076-82.
42. Paya CV, Wilson JA, Espy MJ, et al. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. J Infect Dis 2002; 185:854-60.
43. Razonable RR, Rivero A, Rodriguez A, et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid-organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 2001; 184:1461-4.
44. Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999; 340:1462-70.
45. Gane E, Saliba F, Valdecasas GJ, et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet 1997; 350:1729-33.
46. Valantine HA, Gao SZ, Menon SG, et al. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation 1999; 100:61-6.
47. Razonable RR, Brown RA, Wilson J, et al. The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant recipients with CMV disease. Transplantation 2002; 73: 968-73.
48. Daar ES, Lynn H, Donfield S, et al. Hepatitis C virus load is associated with human immunodeficiency virus type 1 disease progression in hemophiliacs. J Infect Dis 2001; 183:589-95.